Singular Health Group (ASX:SHG) Research & Development: A$0.00 Mil (TTM As of Dec. 2025)


ASX:SHG Singular Health Group Ltd ASX:SHG
30 GF Score
Price A$0.22
GF Value A$0.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Singular Health Group Research & Development?

Singular Health Group ASX:SHG +15.79% 30 Research & Development is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:SHG with a GF Score™ of 30/100 and a GF Value™ of A$0.11 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Singular Health Group's Research & Development for the six months ended in Dec. 2025 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Singular Health Group  (ASX:SHG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Singular Health Group Research & Development Related Terms

Singular Health Group Research & Development Historical Data

* Premium members only.

The historical data trend for Singular Health Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Singular Health Group Research & Development Chart

Singular Health Group Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
0.00 0.00 0.00 0.00 0.00

Singular Health Group Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:SHG
30GF Score
Singular Health Group Ltd ASX:SHG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Singular Health Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.00 Mil mean?
Singular Health Group (ASX:SHG) has a Research & Development of A$0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Singular Health Group and its competitors.
Is Singular Health Group's Research & Development too high?
Singular Health Group's current Research & Development is A$0.00 Mil. Overall, Singular Health Group has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Singular Health Group's Research & Development compare to VEEV and BTSG?
Singular Health Group's Research & Development of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Singular Health Group and its competitors. Singular Health Group's current Research & Development is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singular Health Group stock overvalued right now?
Based on GuruFocus' analysis, Singular Health Group (ASX:SHG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.11, compared to a current price of A$0.22 — trading 100% above its estimated fair value. The current Research & Development is A$0.00 Mil. Singular Health Group's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Singular Health Group (ASX:SHG), the current Research & Development is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Singular Health Group (ASX:SHG) Overvalued in 2026?

Based on GuruFocus' analysis, Singular Health Group stock appears to be overvalued. The current stock price of A$0.22 is trading 100% above its estimated GF Value™ of A$0.11. GuruFocus considers Singular Health Group to be Significantly Overvalued.

Key valuation signals for ASX:SHG:

  • Research & Development: A$0.00 Mil
  • GF Value™: A$0.11 vs. price of A$0.22 (100% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the ASX:SHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Singular Health Group Business Description

Address E3 and E4, 661 Newcastle Street, Leederville, WA, AUS, 6007
Singular Health Group Ltd provides medical software solutions. The company's business segment is the provision of Volume Rendering Platform (VRP) software, providing 3D printing services and 3D machine sales. It operates in one segment, which is the provision and development of medical technology within Australia.
30GF Score

Get the complete analysis for ASX:SHG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.22
Price
A$0.11
GF Value